231 related articles for article (PubMed ID: 27237367)
1. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
2. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
[TBL] [Abstract][Full Text] [Related]
5. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
6. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
[TBL] [Abstract][Full Text] [Related]
7. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
9. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
[TBL] [Abstract][Full Text] [Related]
10. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
11. Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.
Li CF; Liu CX; Li BC; Shen YY; Cui XB; Liu W; Dong HC; Pang LJ; Liang WH; Li F
Int J Clin Exp Pathol; 2014; 7(7):3673-83. PubMed ID: 25120743
[TBL] [Abstract][Full Text] [Related]
12. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Kim JH; Lee JS; Kim EJ; Park KH; Kim KH; Yi SY; Kim HS; Cho YJ; Shin KH; Ahn JB; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Noh SH; Rha SY; Kim HS
Oncotarget; 2016 Apr; 7(17):24549-58. PubMed ID: 27016421
[TBL] [Abstract][Full Text] [Related]
14. Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.
Kapodistrias N; Mavridis K; Batistatou A; Gogou P; Karavasilis V; Sainis I; Briasoulis E; Scorilas A
Oncotarget; 2017 Jan; 8(4):6896-6913. PubMed ID: 28036291
[TBL] [Abstract][Full Text] [Related]
15. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features.
Makise N; Yoshida A; Komiyama M; Nakatani F; Yonemori K; Kawai A; Fukayama M; Hiraoka N
Am J Surg Pathol; 2017 Nov; 41(11):1523-1531. PubMed ID: 28719466
[TBL] [Abstract][Full Text] [Related]
17. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
[TBL] [Abstract][Full Text] [Related]
18. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.
Fiore M; Grosso F; Lo Vullo S; Pennacchioli E; Stacchiotti S; Ferrari A; Collini P; Lozza L; Mariani L; Casali PG; Gronchi A
Cancer; 2007 Jun; 109(12):2522-31. PubMed ID: 17510918
[TBL] [Abstract][Full Text] [Related]
19. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations.
Hoffman A; Ghadimi MP; Demicco EG; Creighton CJ; Torres K; Colombo C; Peng T; Lusby K; Ingram D; Hornick JL; Wang WL; Ravi V; Lazar AJ; Lev D; Pollock RE
Cancer; 2013 May; 119(10):1868-77. PubMed ID: 23401071
[TBL] [Abstract][Full Text] [Related]
20. Differences in recurrence and survival of extremity liposarcoma subtypes.
Vos M; Koseła-Paterczyk H; Rutkowski P; van Leenders GJLH; Normantowicz M; Lecyk A; Sleijfer S; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2018 Sep; 44(9):1391-1397. PubMed ID: 29673808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
